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demonstrate that mutant MGMT after an IRES facilitates the
selection of cells expressing a gene that is therapeutic for a
human disease. This model should be useful for gene therapy of




EUROPEAN EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FOR METASTATIC RENAL CARCINOMA: ON
BEHALF OF THE FRENCH ITAC GROUP AND THE EBMT SOLID
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The immunological graft-versus-tumor (GVT) effect has been
reported in various solid cancers after allogeneic hematopoietic
stem cell transplantation (HSCT). We evaluated the experience
of allogeneic HSCT for renal cell carcinoma (RCC) in Europe.
Methods and Patients: We report the data on 124 patients
with clear cell RCC, median age 52 years (range 18-68) trans-
planted in 21 European centers. Various reduced intensity con-
ditionings (RIC) based on ﬂudarabine were used. All patients
received allogeneic peripheral blood cells: 106 from an HLA-
identical sibling, 5 from mismatched related donor and 13 from
matched unrelated donor (MUD). GVHD prophylaxis consisted
of cyclosporine A (CyA) alone, or combined with methotrexate
or mycophenolate mofetil. All patients with mismatch or MUD
received anti-T-lymphocyte immunoglobulin. Donor lympho-
cyte infusions (DLI) were given to 42 patients. The median
follow-up was 15 months (range 3-41). Results: All but 3
patients engrafted. The cumulative incidence of grades II-IV
acute graft-versus-host disease (GVHD) was 40% and for
chronic GVHD it was 33%. Transplant-related mortality was
16% at one year. Complete (n  4) or partial (n  24) responses,
median 150 (range 42-600) days posttransplant, were associated
with time from diagnosis to HSCT, mismatched donor and
acute GVHD II-IV. Factors associated with survival included
chronic GVHD (hazards ratio, HR 4.12, P  .001), DLI (HR
3.39, P  .001), 3 metastatic sites (HR 2.61, P  .002) and a
Karnofsky score 	70 (HR 2.33, P  .03). Patients with chronic
GVHD and given DLI (n  17) had a 2-year survival of 70%.
Conclusions: Our data demonstrate that i) RCC patients with
less than 3 metastatic locations and a Karnofsky score 	70%
may be considered for HSCT, ii) RIC and allogeneic HSCT is
feasible in RCC patients with a low non-progression-mortality
(16%), iii) a clinically meaningful GVT effect can be generat-




GENE EXPRESSION ANALYSIS OF CIRCULATING HEMATOPOIETIC PRO-
GENITOR CELLS FROM IRRADIATED MICE AND HUMANS PROVIDES A
MOLECULAR PROFILE OF RADIATION INJURY
Chute, J.P., Muramoto, G., Dressman, H., Chao, N.J., Nevins, J. Duke
University, Durham, NC.
The risk for terrorist-mediated nuclear or radiological attack has
been identiﬁed as a major threat to the United States in the coming
decade. Radiation exposure can cause a spectrum of hematological
toxicities, from mild immunosuppression to myeloablation with
concordant life threatening complications. Accurate biological do-
simetry will be critical, therefore, for caregivers to triage individ-
uals to the appropriate medical management. Currently, biodosi-
metric tools include lymphocyte depletion kinetic and cytogenetic
analysis, both of which require several days for results to be ob-
tained. We propose that high throughput genomic analysis of
peripheral blood mononuclear cells (PB MNCs) can sensitively
identify patterns of molecular changes which occur following dif-
ferent levels of radiation exposure. In this study, we collected
primary PB MNCs from 10 week old C57Bl6 mice at 6 hours
following 4 different levels of radiation exposure: normal (non-
irradiated), 50 cGy (trivial exposure), 200 cGy (myelosuppressive)
and 1000 cGy (lethal). RNA was extracted and used for synthesis of
probes for hybridization to spotted arrays. We performed a binary
regression analysis to elucidate patterns of gene expression to
distinguish between a normal animal and one that had been ex-
posed to various levels of radiation. Distinct gene expression pat-
terns were evident within PB MNCs at each of the 4 exposure
levels, demonstrating the feasibility of this approach. We found
that the selected metagene pattern for “normal” was able to dis-
tinguish normal from 50 cGy, 200 cGy and 1000 cGy exposure
with 100% predictive capacity. The predictors selected for 50 cGy,
200 cGy and 1000 cGy were equally powerful at distinguishing
these levels of exposure from all others. These data demonstrate
the power of this approach to correctly distinguish clinically rele-
vant levels of radiation exposure. In order to validate these molec-
ular predictors generated in mice as proﬁles of human radiation
response, we are currently testing, in a blinded manner, whether
these predictors can distinguish different levels of radiation expo-
sure in human PB samples collected from patients who have un-
dergone 200 cGy or 1000 cGy total body irradiation. These vali-
dated biomarkers of radiation response can serve as templates for
rapid screening tests for radiation exposure and, more broadly, are
potential targets for therapeutic intervention.
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A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF VELAFERMIN
(CG53135-05) ADMINISTERED INTRAVENOUSLY AS A SINGLE DOSE
FOR THE PREVENTION OF ORAL MUCOSITIS IN PATIENTS RECEIVING
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT)
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Velafermin (CG53135-05 or recombinant human ﬁbroblast
growth factor-20) is under investigation for the prevention of
oral mucositis (OM). OM is a common side effect in patients
(pts) receiving high-dose chemotherapy (HDCT) with or with-
out total body irradiation (TBI) as conditioning regimen for
AHSCT. Preclinical studies have demonstrated that velafermin
promotes epithelial and mesenchymal cell proliferation in vitro
and that a single dose of velafermin had activities in reducing
the severity and duration of OM as effective as multiple doses.
Previous clinical data suggested that velafermin could be safely
given at doses up to 0.2 mg/kg. The objectives of this phase II
trial were to evaluate the safety and efﬁcacy of velafermin in
preventing severe OM from approximately 200 pts undergoing
HDCT with or without TBI for an AHSCT in the US. Patients
were equally randomized to one of four arms: placebo, or
velafermin 0.03, 0.1 or 0.2 mg/kg. Pts received a single intra-
venous dose of velafermin or placebo 24-36 hrs after completion
of the stem cell infusion and were monitored daily until they
were discharged from the hospital or until neutrophil engraft-
ment established (deﬁned as ﬁrst day of absolute neutrophil
counts 500/ in this study). The primary end point was the
incidence of OM (World Health Organization (WHO) score of
grade 3 or 4). Secondary end points included duration of severe
OM, area under the curve of all OM, days with alternative
nutrition, and narcotic analgesic use. Patient enrollment was
completed with 212 pts randomized. Approximately 2/3 were
multiple myeloma pts receiving high dose melphalan as condi-
tioning regimen and 1/3 of them were lymphoma pts. Less than
10% of pts had TBI as part of their conditioning regimen.
Preliminary blinded aggregate data from 160 pts indicated that
study drug was generally well tolerated. 30% of pts did not
develop any OM and 32% pts developed grade 3/4 OM with a
duration of 4.8  3.7 (mean  sd) days among the pts with
severe OM. Most adverse events (AE) were mild to moderate in
severity with most frequent serious AEs being neutropenic
fever, pneumonia and pyrexia. The trial was monitored by a
Data Safety Monitoring Board (DSMB). The results of the
primary end point of grade 3/4 OM from each treatment arm or
placebo as well as 30-day safety information from all pts will be
reported.
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INVASIVE ASPERGILLOSIS FOLLOWING HSCT: OUTCOMES AND PROG-
NOSTIC FACTORS ASSOCIATED WITH MORTALITY
Upton, A.1, Kirby, K.A.1, Boeckh, M.1,2, Carpenter, P.A.1,2,
Marr, K.A.1,2 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA.
Invasive aspergillosis (IA) is a common cause of infection-related
mortality in hematopoietic stem cell transplant (HSCT) recipients,
despite appropriate therapy. Factors inﬂuencing outcomes have
not been fully elucidated. To determine prognostic factors associ-
ated with mortality we retrospectively reviewed all cases of proven
and probable IA diagnosed in HSCT recipients at the Fred
Hutchinson Cancer Research Center (FHCRC) from 1st Jan 1990
to 31st Dec 2004. All-cause and attributable mortality were re-
corded. Prognostic factors identiﬁed in univariate analysis (P 
.10) were further analyzed using a Cox multiple regression model.
All variables except those occurring before HSCT were modeled as
time dependent. 408 cases were identiﬁed: 238 proven and 170
probable IA. The probability of overall mortality at 1 year after
diagnosis was 70% in patients diagnosed from 2002 to 2004 versus
86% among those diagnosed prior to 2002 (P  .0001). Cord
blood as stem cell source (HR  3.7 [1.0-13.2]), severe pulmonary
function test abnormality pre-HSCT (2.3 [1.2-4.2]), increased cre-
atinine (2.9 [1.9-4.3]) and bilirubin (6.2 [4.4-8.7]) at time of diag-
nosis of IA, monocytopenia (2.3 [1.6-3.2]), CMV disease (1.4 [1.0-
1.8]), receipt of antithymocyte globulin (2.2 [1.5-3.3]),
disseminated IA (2.0 [1.4-2.7]), and IA later after HSCT (	40
days) (2.8 [2.0-4.1]) were independently associated with increased
all-cause mortality; receipt of non-myeloablative HSCT (0.5 [0.3-
0.7]) was independently associated with decreased mortality. The
probability of mortality attributable to IA at 1-year was 26% in
patients diagnosed from 2002 to 2004 versus 49% among those
diagnosed prior to 2002 (P  .007). Mismatched HSCT (2.1
[1.2-3.7]), increased creatinine (3.3 [1.8-6.1]) and bilirubin (5.5
[3.3-9.3]), receipt of antithymocyte globulin (2.3 [1.2-4.1]), dissem-
inated IA (4.0 [2.5-6.3]) and IA later after HSCT (2.4 [1.2-4.0])
were independently associated with increased attributable mortal-
ity; non-myeloablative HSCT (0.3 [0.1-0.8]) and receipt of vori-
conazole therapy (0.4 [0.2-0.8]) were independently associated with
decreased mortality. In this study we have demonstrated a signif-
icant decline in mortality in patients diagnosed with IA following
HSCT in the time period 2002-2004, compared with prior to
2002. This ﬁnding has coincided with increased use of non-my-
eloablative conditioning regimens and voriconazole; two factors we
have identiﬁed to be protective.
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